S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor
cells and slow the growth of cancer of the urinary tract.
PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have
advanced cancer of the urinary tract.